Research programme: NR2F6 receptor modulators - Regen BioPharmaAlternative Names: RG NA01; RG NA02; RG NI01; RG NI02
Latest Information Update: 09 Mar 2017
At a glance
- Originator Regen BioPharma
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Orphan nuclear receptor agonists; Orphan nuclear receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer